|
WHAT'S THIS?
|
RECENT ADDITIONS
|
New information that is relevant to publication planning, is constantly being added to this freely accessible resource.
The latest additions are highlighted below, the rest can be found via the menu on the left. We welcome ideas and contributions from our visitors so please join in and help spread the word.
|
|
|
LATEST COMMENTARY
|
|
Access to data in industry-sponsored trials
Published 10 December 2011
This article by Andreas Lundh and colleagues in The Lancet, highlights the confusion over what is meant by "full access to data" and concludes that we should work towards a situation in which anonymised raw data are made freely available to the public. Saying "Our patients deserve nothing less than this, which would be highly beneficial for health care."
[Link to original source material]
|
|
|
Ghosts in the machine
Published 6 December 2011
Ghostwriting in medical publishing on behalf of big drug companies has a long history, finds Rachel Hendrick in this BMJ article, and oversight of the practice has its problems.
[Link to original source material]
|
|
|
Publication of clinical trial data: enough of the excuses!
Published 29 November 2011
How much negative data goes unpublished? Ryan Woodrow set to find out and his surprising results are detailed here in an article in pharmaphorum.
[Link to original source material]
|
|
|
Effect of using reporting guidelines during peer review on quality of final manuscripts submitted to a biomedical journal: masked randomised trial
Published 22 November 2011
E Cobo and colleagues conclude in their BMJ article that additional reviews based on reporting guidelines improve manuscript quality, although the observed effect was smaller than hypothesised and not definitively demonstrated..
[Link to original source material]
|
|
|
Ghostwriting: myths and realities - part 2
Published 8 November 2011
Adam Jacobs continues with his myth-busting article in pharmaphorum and says "the fact is that we simply don't know how many papers are ghostwritten".
[Link to original source material]
|
|
|
Ghostwriting: myths and realities - part 1
Published 1 November 2011
Adam Jacobs writes in pharmaphorum and says "there's been a lot of guff written about medical ghostwriting lately, in blogs, in the mainstream media, and in peer-reviewed journals".
[Link to original source material]
|
|
|
Honorary and ghost authorship
Published 25 October 2011
Patricia Baskin and Robert Gross of Neurology write in the BMJ, about their approach to honorary and ghost authorship in their journal.
[Link to original source material]
|
|
|
Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey
Published 25 October 2011
In this OA article in the BMJ, Jospeh Wislar and others report evidence of honorary and ghost authorship in 21% of articles published in major medical journals in 2008.
[Link to original source material]
|
|
|
Should journals sell reprints?
Published 14 October 2011
A Head to Head feature in the BMJ:
Should journals sell reprints? Yes - from Jane Smith
Should journals sell reprints? No - from Tom Jefferson
[Link to original source material - YES]
[Link to original source material - NO]
|
|
|
Letting the sunshine in on doctor-pharma relationships
Published 11 October 2011
In this Feature article in the BMJ, Andrew Jack writes that drug companies are increasingly obliged to publish details of payments to doctors. The United States is leading the charge, but are we getting the full story in Europe?
[Link to original source material]
|
|
LATEST PRESS RELEASES
|
|
Wolters Kluwer Reaches Definitive Agreement to Sell Its Pharma-Related Marketing & Publishing Services Business to Springer
Published 9 November 2011
From Wolters Kluwer Pharma Solutions
[Access full article here].
|
|
WHAT ELSE?
|
NEWS ALERT!
Do you want to be alerted to important news and events relevant to publication planning?
Sign up here.
|
|
|
The latest jobs at NextMedCommsJob needing publications planning expertise...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
